

Canntab Therapeutics Ltd

18:39 21 May 2019

Buds & Duds: Cannabis stocks climb; Canntab shares soar on hemp-cultivation licence

Cannabis stocks went on a topsy-turvy ride Tuesday, with a mix of winners and losers across US and Canadian markets.

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, was up 0.3% to 274.9 points on Tuesday. The Horizons Marijuana Life Sciences Index ETF was up 0.8% at C\$20.19.

Buds

Canntab Therapeutics Ltd (CSE:PILL.CN) (OTCMKTS:CTABF) shares soared Tuesday after it announced it has received an industrial hemp cultivation licence from Health Canada in a major milestone for the cannabis company.

Shares of the firm were up 10% at C\$0.77 in Canadian trading.

The licence allows Canntab to cultivate industrial hemp. Canntab intends to use the licence to secure a large amount of hemp biomass that it will use to extract cannabidiol (CBD) to manufacture cannabis hard pills.

READ: Canntab Therapeutics hits new milestone with hemp-processing licence from Health Canada

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) shares were on the rise Tuesday after it announced its research team has been approved to acquire human nasal tissue for the final phase of the cannabinoid-based, soluble gel, called Sol-gel.

Shares of the company jumped 18.2% at C\$0.07 in Canadian trading.

Preveceutical said it believes that the outcomes of its Sol-gel program may be of value to companies with an interest in delivering cannabinoid/cannabis-based-derived pharmaceuticals to the central nervous system.

READ: PreveCeutical Medical wins approval to acquire human tissue for final phase of Sol-gel technology testing

Other gainers Tuesday included Cronos Group Inc (NASDAQ:CRON) (TSE:CRON), which was up 5.8% at US\$15.60 in New York, up 4.2% at C\$20.91 in Toronto.

Duds

The Supreme Cannabis Company Inc (TSE:FIRE) (OTCMKTS:SPRWF) shares nudged down on Tuesday, down 1.4% at US\$1.41, up 1.4% at C\$1.89 in Toronto.

On Friday, the firm announced plans to acquire Langley, BC-based producer BlissCo Cannabis Corp (CSE:BLIS) in an all-stock deal it valued at C\$48 million.

Blissco has a 18,000 sq/ft production facility and produces cannabis oils. It received its production license in August 2018.

Price: 0.73

Market Cap: \$24.14 m

1 Year Share Price Graph



Share Information

Code: PILL

Listing: CSE

52 week High Low
 1.15 0.27

Sector: Cannabis

Website: canntab.ca

Company Synopsis:

Canntab Therapeutics was founded on April 20, 2016 by pharmaceutical industry professionals who saw an urgent need to add industry rigour and professionalism to the medicinal cannabis market. We are the first company solely dedicated to the research and development of oral dosage therapeutic formulations of cannabis.

action@proactiveinvestors.com

Shares of CBD manufacture Isodiol International Inc (CSE:ISOL) (OTCQB:ISOLF) dropped Tuesday, down 6.2% to US\$0.77. The stock has struggled in recent weeks, on the back of challenges in Mexico, a result of changes by the Mexico's Federal Commission for the Protection against Sanitary Risk (COFEPRIS) surrounding CBD regulation and licenses.

Contact Katie Lewis at katie@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).